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controversy was reported, and whose language was used to
explain the issues to the public. While the scientific con-
troversy remains, the case provides an opportunity to exam-
ine the role of the press in supporting public access to
evidence about health care.
2. Methodology
The analysis began from two perspectives. The purpose of
the simple content analysis was to summarize the content
and structure of the articles. The content categories to be
investigated were: (1) what the press presented as the
important issues in whether mammography should or should
not be performed, (2) what sources of evidence were chosen
to represent both sides, and (3) what story lines reporters
used to organize the information. A second perspective was
the consumer choice analysis. That perspective led us to look
for information that would be useful to patients in making an
informed choice for themselves. The elements looked for
were: (1) pros and cons of screening versus not screening for
a population and for an individual, and (2) effectiveness of
treatment (should breast cancer be identified) under screen-
ing and no screening conditions. Pros and cons looked for
were likelihood of finding cancer, and likelihood of dying of
cancer, and the patient concerns that are generated by false
positive and false negative mammography results. Since the
Gotzsche and Olsen meta-analysis claimed to demonstrate
that a screening test was not justified, in terms of the
numbers of lives saved with and without screening, we
began expecting these to be the core of the press reporting.
The data source was a comprehensive set of newspaper
articles collected by the National Health Service Breast-
Cancer Screening Programme covering the 10 days follow-
ing the January 7, 2000 press release [2]. This included 148
articles in 113 different newspapers from across the UK. All
the newspapers reviewed are listed in Appendix A. In a hand
search, screening programme staff reviewed all the papers
each day during the period and clipped the full text of the
article. The data were collected for the purpose of tracking
the press coverage. They were made available for indepen-
dent analysis at the request of the investigators.
The first step was for both authors to read all the articles.
The second step was to develop a set of categories for the
simple content analysis and the consumer choice analysis.
The latter produced so little codable data that it was aban-
doned. The answer to the first question (what are the issues)
was resolved by consensus of the investigators. The main
issue was, ‘‘Should the government abandon screening?’’
The second question (sources of evidence) was infrequently
the scientific evidence discussed in the meta-analysis. Each
article had at least one reference to an expert. For that
reason, the content category became, who was quoted, or
‘‘proportion of quotations by source.’’ This was a simple
count of which authorities were quoted. The total list was
five. Each article was then coded according to the presence
or absence of a quotation from each of the authorities. On the
first read through, the first author made a list of main themes
(those reported as headlines or discussed in the first para-
graph of the news article). Those were: (1) Is the Govern-
ment wasting time or money? (2) Does the mammography
controversy have budget cutting implications, or is it an
attempt by the Government to save money in the budget? (3)
Has anyone been injured? (4) Has anyone been saved? (5)
Would eliminating mammography discriminate against
women or the elderly? The second author (SC) developed
a coding system to count mentions of these themes. How-
ever, she found additional themes found additional pieces of
information that journalists supplied to support the screen-
ing programme. These, again, were not found in the Lancet
article, but supplied the local context for the press. The
screening programme related information cited frequently
were: (1) amount of money spent, (2) numbers of women
affected, and (3) pending Government decisions to expand
breast-cancer screening. Articles were coded as present or
absent for each of the three programmme items.
The specific core content cited by the press to evaluate the
two sides of the argument about whether to breast cancer
saved lives were largely not those found in the Gotzsche
article. The data cited most frequently were: (1) numbers of
cancers found, (2) size of tumors at detection, (3) numbers of
lives saved as quoted in screening programmed documents
(not the Gotzsche article), and (4) mortality rates for the
nation. The most frequently cited information item from the
Lancet was not from the Gotzsche article, but from the
opposing commentary by Dr. Harry de Koning, of the
Rotterdam Department of Public Health in the Netherlands.
Dr. de Koning was quoted as saying that Gotzsche and Olsen
have ignored the fact that other factors probably have a more
important part in lowering the mortality rate through screen-
ing. Articles were coded for presence or absence of each of
these screening effectiveness items.
After the codes were developed, a sample was tested for
reproducibility by the two authors. Once agreement was
confirmed on the first 10 articles, all were subsequently
coded by the second author (SC), and checked by the first
author. A text unit for the purposes of counting presence or
absence of content items was the entire article, defined as
any text found on the same page, or a continuous flow of
dialogue if the article carried over to another page. This was
to avoid double counting sources. The length of the text cited
was not calculated. We excluded articles that were exact
duplicates, articles unrelated to the Lancet article, articles
that were exclusively editorials or commentaries, and letters
to the editor.
Initially, the entire set of articles were coded as one
group. However, as coding progressed, the frequencies
suggested that a shift in emphasis occurred over time.
The shift appeared to be roughly between the first and
second weeks of coverage. We, therefore, divided articles
into two groups chronologically. Wave 1 included articles
that appeared the Friday after the press release, January 7,
2000, through the following Sunday, January 9, 2000. Wave
1 contained the initial bolus of information reporting and
interpretation. Wave 2 included articles that appeared during
the second week (10 21 January), when the January 8, 2000
issue would have been widely available to the medical expert
community. All articles were read a second time and coded.
Since most were short, we coded specific information types
as absent or present. We did not estimate the proportion of
the article taken up by a specific topic. We identified five
primary sets of stakeholders in the controversy: the original
authors, the author of the invited commentary, medical
Lancetexperts, breast-cancer advocates, and screening pro-
gramme spokespersons. Phrases representing the original
authors were coded as author quotes if they were direct
quotations from the press release, the original article, or a
recent interview in which they discussed the results of the
article [3]. Invited commentary in the Lancet referred to the
commentary in the same issue by Koning [4]. A non-author
expert was any cancer researcher or physician working in a
cancer unit. Advocates were any representatives of cancer
advocacy or charity groups. Finally, screening programme
spokespersons included any quote from a public health
minister, or other official working with the screening pro-
gramme at a national or local level.
The content categories were: (1) stakeholder sources
quoted, and (2) information types reported. Information
types differentiate between personal interest stories about
individual women who had undergone mammography, and
technical aspects of screening or treatment, and statistics
about the screening programme. Technical aspects included
comments about methods (i.e. randomisation), differences in
study subject characteristics, and other aspects of the design
and execution of the meta-analysis. Lastly, we coded use of
any data about the current screening programme, including
screening rates, breast-cancer incidence and mortality under
present screening policies, money spent, and claims to lives
saved. Money spent on the screening programme included
references to the amount of money spent by the UK National
Health Service per year and estimates of expenditures per
person.
3. Results
3.1. Stakeholders quoted
A shift occurred from Wave 1 to Wave 2, in the proportion
of articles that included author or commentary direct quotes.
Wave 1 articles included a greater proportion of quotes
from all stakeholders except the screening programme.
Wave 2 articles were more likely to cite the screening
programme. Articles including quotes from the original
authors decreased from 74 to 30% in the second week
following publication of the Lancet article (Wave 2). All
except two or three quotations were from the original
press release or article. Almost all were the same quote,
‘‘Screening for breast cancer with mammography is unjus-
tified’’ [5]. As indicated in Table 1, there was a shift in Wave
2 toward quoting the screening programme officials.
3.2. Information type presented
Use of testimonials increased in Wave 2, while technical
aspects, such as whether the reviewed studies were properly
randomized, decreased, as did inclusion of data about the
screening programme (Tables 2 and 3).
References to numbers of cancers found, tumor size, lives
saved, and mortality rates were similar across waves. Num-
ber of cancers found was given either as average per year or
the absolute number in a specific year was given. Size of
tumors was reported either as ‘‘too small to be felt by hand’’
or was given in millimetres. Mention of tumor size at
detection was rare in both waves. Number of lives saved
was reported as either the average per year, or an estimate of
lives saved over the first decade (since screening began).
Table 1
Proportion of quotations by source
Wave 1
(January 7 9)
Wave 2
(January 10 21)
Original authors 77 (74%) 13 (30%)
Reference to Koning 43 (41%) 4 (9%)
Expert quote 55 (53%) 12 (27%)
Advocate quote 50 (48%) 5 (11%)
Screening programme quote 56 (54%) 28 (64%)
Total articles 104 44
Table 2
Information type
Wave 1
(January 7 9)
Wave 2
(January 10 21)
Testimonials 13 (13%) 16 (36%)
Technical aspects 62 (60%) 17 (39%)
Total articles 104 44
Table 3
Information cited about the screening programme
Wave 1
(January 7 9)
Wave 2
(January 10 21)
Programme related
Money spent 61 (59%) 6 (14%)
Number of women involved 17 (16%) 15 (34%)
Comments about expanding
the programmme
48 (46%) 7 (16%)
Effectiveness
Number of cancers found 35 (37%) 12 (27%)
Size of tumor 8 (8%) 5 (11%)
Number of lives saved 27 (26%) 10 (23%)
Mortality rates 35 (37%) 15 (34%)
Koning quote (about
mortality rates)
22 (21%) 0 (0%)
Total articles 104 44
How ‘‘lives saved’’ was determined was not given. Mortality
was given either as the decline in mortality from breast cancer
(overall or per year) or current death rates from cancer. The
most common estimate was a 14% drop in mortality from
1989 to 1998 [6] as well as references to statistics to be
released later in the year that would demonstrate a ‘‘signifi-
cant reduction in mortality from breast cancer’’ [7]. Many
articles quoted the de Koning commentary, ‘‘In the UK there
has been a clear reduction in breast-cancer mortality due in
part to screening’’ [8].
In Wave 2, there were fewer references to money spent or
to a possibility of expanding the programme. Per year
estimates of the amount of money spent on the screening
programme ranged from £36 to 42 million. References to the
amount of money spent on the screening programme repre-
sented the most dramatic decrease from the first Wave 1
(59%) to Wave 2 (14%). The direct quote from de Koning
about falling mortality rates disappeared in Wave 2. Wave 1,
in general, focused on the controversy and the radical claims
of Goetzsche and Olson; Wave 2 tended to reaffirm support
for the current screening programme, including patient
testimonials and general information about the screening
programme.
3.3. Article structure and focus
The typical structure for a Wave 1 article was a ‘‘point/
counterpoint’’. The opening typically announced the ‘‘con-
troversial’’ Lancet article followed by a brief description of
the findings (e.g. mammography ‘‘unjustified,’’ previous
studies lacked proper randomisation). This was followed by
a counterpoint (e.g. citation of the ‘‘dismay’’ expressed by
cancer advocates and experts). While some included quotes
from experts who were critical of the screening programme,
most included only positive quotes in this section. The
dominant message in this section urged women to ignore
the study and continue to attend screening appointments.
Many also expressed ‘‘fear’’ that women would quit going
for screenings. Following the point/counterpoint, most
articles (59%) included description of expenditures per
year on the NHS screening programme. This was fre-
quently followed by a brief comment about support for
or criticism of the programme. For example, ‘‘Supporters of
the programme argue that the cost is worthwhile as it saves
lives and there are strong moves to extend the age limit.
Some suggested that the money would be better spent
improving treatment for breast cancer and searching for
new therapies’’ [9]. Sometimes, this statement was sup-
ported with statistics or expert quotes, but more often it was
not. Finally, the articles usually ended with either more
details about the Lancet article or some positive quote about
screening.
In contrast, Wave 2 articles focused more on testimonials
or general information about the current screening pro-
gramme. The format was less uniform, but generally
adopted one of these foci. Testimonials frequently included
detailed accounts of personal experience with cancer and
screening sometimes including general statistics about the
current screening programme. Some featured not personal
experience, but quotations from opinion leaders, celebrities
or experts who ‘‘urged’’ women to continue screening or
simply argued for why screening ‘‘works’’ or is important.
Theoretical arguments they gave for why women should
participate in screening included: it can detect cancers too
small to be felt by hand, better chance of recovery, spares
women disfiguring surgery, etc. The articles in Wave 2 also
usually included a few details from the Lancet article
followed by quotes from experts and/or statistics about
the current screening programme. Information about the
screening programme tended to shift from an emphasis in
Wave 1 on the amount of money spent to an emphasis in
Wave 2 on the number of women screened (and presumably
helped or re-assured as the articles put it).
The shift in focus and structure of Wave 1 (point/counter-
point) and Wave 2 (testimonials/support for the screening
programme) was accompanied by an increase in quotes from
the screening programme of 10% and a decrease in data
about the screening programme of 15%. In Wave 1, writers
cited advocates and non-author experts as the authority; in
Wave 2, the screening programme was cited as the authority.
By the second week (Wave 2), the data shifted, in context of
support for the screening programme, to tumor size on
detection and numbers of women screened.
A final structural issue is that of who are the implied
parties to the debate. The answer seems to be that the press
cast it as an internal argument among experts that the public
could not join. An exception is found in several quotes from
experts in Wave 1 articles. These are instructive: ‘‘There are
flaws in the way it [Goezsche’s article] is written. For
example, many of the studies looked at are very old.
Mammography techniques have improved greatly in recent
years’’ [10], and ‘‘. . . a statistically significant difference in
age is not necessarily study significant or a serious bias in
screening trials’’ [11].
These experts try to make the elements of the controversy
accessible to the reading public. However, it should also be
noted that these more descriptive quotations were mostly
found in scientific journals rather than in the mainstream
press.
4. Conclusions
The discussion in the press of this complicated and
provocative meta-analysis was conducted in both waves
of articles within a framework fairly typical of discussions
of medical news. What is newsworthy is the frequency of
the ‘‘medical breakthroughs’’ and human interest stories of
how a life was saved. This approach is extended (and further
polarized) by the point/counterpoint approach of citing
experts and advocates who are either for or against the
status quo of treatment policy or programme policy. What
this approach does not do is deal with medical uncertainty.
While the public is accustomed to scandal (i.e. ‘‘getting
dirt’’ on ministers, doctors, and other participants in the
health care arena), this approach does not ultimately support
evidence-based patient decision-making or evidence-based
policy. If the public is to become accustomed to making
personal health care decisions that reflect their own prefer-
ences and a realistic understanding of their chances of
benefit or harm with and without medical intervention, they
need a different kind of information. Nowhere in the report-
ing of the coverage of the Gotzsche and Olsen article, does a
newspaper include in the background information that 90%
of positive mammograms are normal breasts (e.g. ‘‘false
positives’’) that must be investigated further because mam-
mography is not perfectly diagnostic [12].
An immediate concern about presenting medical uncer-
tainty to the public is whether the average reader can
understand probabilistic information. The evidence to date
from randomized studies of individual patient decision-
making suggests that they can [13,14], and that dealing with
uncertainty does make patients more anxious. Studies of
patient attitudes toward medical information show univer-
sally that patients want information, whether or not they
want to share in decision-making [15].
How should false negative and false positive laboratory
test results be discussed with patients? How should the
policy question of whether mammography is effective be
discussed? We suggest that patients be introduced to back-
ground information about mammography, the incidence of
breast cancer, and the mortality of screened and unscreened
patients. This would require introducing ideas with which
many clinicians are uncomfortable, like false positive and
false negative rates and negative and positive predictive
power. False positives could be framed as ‘‘excess biop-
sies’’; false negatives could be framed as ‘‘false reassur-
ance’’ rates. This would allow discussion of issues of the
following type:
 What will happen if a patient is not screened?
 What are the alternatives for protecting oneself from
cancer?
 Are there any potential harms from screening and follow-
up, and how often do they occur?
One of the issues highlighted by this controversy is a
subtle one about who are the parties to the scientific argu-
ment. We have suggested that the media cast the argument in
this case as being between scientists. The subtle implication
of this approach is that the public cannot understand the
issues. If health care discussion is to become less paterna-
listic and include the patients, policy-makers, and the
experts, then all must be party to the discussion. One
ultimate benefit of introducing patients to false results from
mammography is that the public and policy-makers may be
able to accept the limitations of technologies and not over
react in either a positive or a negative fashion. Given the
continuing mammography controversy [16], health profes-
sionals and the press now have the opportunity to pioneer a
new approach in the context of the breast-cancer screening
controversy.
4.1. Practice implications
How can clinicians address this new educational chal-
lenge among patients who may have been introduced to the
mammography debate by the press? They will need to
explain that (1) mammograms have never given 100%
perfect information regarding the presence or absence of
breast cancer, (2) why the inherent uncertainty resulting
from laboratory findings is generating a policy debate about
whether national health services should provide mammo-
graphy, and (3) whether the debate should influence indi-
vidual patient decisions about mammography. This
challenge is likely to become increasingly prevalent, as
screening tests like mammography, and prostate specific
antigen for prostate cancer continue to be debated. We
suggest that clinicians confront this challenge by explaining
the concepts of false results to patients, and explaining that
they are not mistakes, but an inevitable characteristic of
diagnostic tests. Educating patients about this new, and
potentially disturbing, idea should, ultimately, improve
patients’ ability to make informed decisions screening
and treatment choices.
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Appendix A. Titles of newspapers
(in alphabetical order)
Aberdeen Press and Journal
Barnesley Star
Bath Chronicle
Belfast Telegraph
Birmingham Post
Blackpool Gazette
Bradford Telegraph and Argus
Bristol Evening Post
BMJ
Burton Daily Mail
Chorley Citizen
Colchester Evening Gazette
Corby Evening Telegraph
Coventry Evening Telegraph
Craven Herald and Pioneer
Croydon Adviser
Cynon Valley Leader
Daily Mail
Daily Mirror
Daily Post
Daily Record
Daily Telegraph
Darlington and Stockton Times
Derby Evening Telegraph
Doctor
Doncaster Star
Dorsett Evening News
Dundee Courier and Advertiser
East Anglian Daily
Eastern Evening News
Edinburgh Evening News
Evening Echo
Evening Standard
Exeter Express and Echo
The Express
Financial Times
Glasgow Evening Times
The Guardian
Guernsey Press and Star
Halifax Evening Courier
Health and Ageing
Heartland Evening News
The Herald
Herald of Wales
Hospital Doctor
Huddersfield Daily Examiner
The Independent
Ipswich Evening Star
Irish Independent
The Irish Times
Irvine Herald
Irvine Times
Jersey Evening Post
Keighley News
Kentish Express
Kettering Evening Telegraph
Kidderminster Express and Star
Lancashire Evening Post
Leicester Mercury
Leigh Tyldesley and Atherton Journal
Lichfield and Burntwood Express and Star
Lincolnshire Echo
Liverpool Echo
Longride and Ribble Valley News
Maidenhead Advertiser
Manchester Evening News
Manchester Metro News
Manx Independent
Medical Monitor
Metro London
Metro North West
The Mirror
New Scientist
The News
News and Star
Newcastle Upon the Tyne Evening Chronicle
Newcastle Upon the Tyne Journal
North West Evening Mail
Northampton Chronicle and Echo
Northern Echo
Nottingham Evening Post
Nuneaton Evening Telegraph
Nursing Standard
Nursing Times
Oxford Mail
Peterborough Evening Telegraph
The Planet
Plymouth Evening Herald
Practice Nursing
Pulse
Richmond Comet
Rotherham Star
Scarborough Evening News
The Scotsman
Shippy Gazette
Shropshire Star
South Wales Argus
South Wales Echo
South Wales Evening Post
Southern Reporter
Stafford Express and Star
The Star
Swindon Evening Advertiser
The Times
Ulster News Letter
Uxbridge and West Drayton Gazette
Western Daily Press
Western Mail
Western Morning News
Wigan Evening Post
Wolverhampton Express and Star
Yorkshire Evening Press
Yorkshire Evening Post
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